Navigation Links
Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
Date:5/6/2008

United Therapeutics to Hold Investor Q&A Session Following Conclusion of

ATS Conference

SILVER SPRING, Md., May 6 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the American Thoracic Society (ATS), to be held in Toronto, Ontario, beginning May 16th and ending May 21, 2008, including the first public presentation of the full data set from the TRIUMPH-1 study of inhaled treprostinil. Additional information concerning presentation topics and times may be accessed via the ATS conference website or at http://ir.unither.com/events.cfm.

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Lewis Rubin, MD, Director of the Pulmonary Hypertension Program at the University of California San Diego, and Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will participate in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Lung Rx, Inc. is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products. [uthr-g]


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
2. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
6. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
7. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
10. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
11. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... Feb. 5, 2016  Patients in Alabama ... ultrasound (HIFU) therapy no longer have to travel out of ... partnership with Urology Centers of Alabama to provide ... procedure for qualifying patients. Alabama ... the treatment of prostate cancer using many different modalities. They ...
(Date:2/5/2016)... Feb. 5, 2016 ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the ... started in 2003. This year, he ran all 26.2 miles with a green 25-pound ... the Miami Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
Breaking Medicine News(10 mins):